GW501516 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
As garnet starts breaking down in the later stage of metamorphism, monazite rims rich in Y and HREE will form. The extent of fractionation of Y between garnet and monazite is also found to be related to temperature. It is thus used as a thermometer, providing temperature constraints on the P-T path.
Etoxadrol (CL-1848C) is a dissociative anaesthetic drug that has been found to be an NMDA antagonist and produce similar effects to PCP in animals. Etoxadrol, along with another related drug dexoxadrol, were developed as analgesics for use in humans, but development was discontinued in the late 1970s after patients reported side effects such as nightmares and hallucinations.
In animals and humans, orexin receptor agonists such as orexin-A and danavorexton dose-dependently produce wakefulness and locomotor activity while orexin receptor antagonists like suvorexant transiently reduce locomotor activity and dose-dependently promote sleep. Acute orexin receptor antagonists can promote sleep in animals to a greater extent than what occurs in narcolepsy-like orexin system loss. In addition, little to no cataplexy has been observed even with high doses of orexin receptor antagonists in animals and humans. It is unknown if long-term use of orexin receptor antagonists may produce compensatory neural changes or narcolepsy-like symptoms. An animal study of chronic high-dose suvorexant administration that showed development of narcolepsy-like changes suggests that this may be possible however. Endogenous orexinergic tone is expected to play an important moderating influence in terms of the effects of orexin receptor modulators. As an example, rising orexin levels during the day may help to competitively offset the next-day residual effects of nightly-dosed orexin receptor antagonists.
== External links == Histology at utmb.edu Histology image: 36_02 at the University of Oklahoma Health Sciences Center - "ureter" Histology image: 37_02 at the University of Oklahoma Health Sciences Center - "urinary bladder" Anatomy Atlases – Microscopic Anatomy, plate 02.24 - "Transitional Epithelium", Ureter Histology at KUMC urinary-renal16 "ureter" www.urothelium.com is an online resource for information about Human Urothelium and the "Biomimetic Urothelium" Archived 2011-02-01 at the Wayback Machine Urothelium at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Histology at qmul.ac.uk Archived 2011-07-21 at the Wayback Machine Diagram at umich.edu Archived 2006-09-10 at the Wayback Machine Histology at wisc.edu Archived 2008-06-10 at the Wayback Machine
US575002A patent on 01.Dec.1897 to Alexander Lodyguine (Lodygin, Russia) describes filaments made of rare metals, amongst them was tungsten. Lodygin invented a process where rare metals such as tungsten can be chemically treated and heat-vaporized onto an electrically heated thread-like wire (platinum, carbon, gold) acting as a temporary base or skeletal form. (US patent 575,002). Lodygin later sold the patent rights to General Electric. In 1902, Siemens developed a tantalum lamp filament that was more efficient than even graphitized carbon filaments since they could operate at higher temperature. Since tantalum metal has a lower resistivity than carbon, the tantalum lamp filament was quite long and required multiple internal supports. The metal filament gradually shortened in use; the filaments were installed with large slack loops. Lamps used for several hundred hours became quite fragile. Metal filaments had the property of breaking and re-welding, though this would usually decrease resistance and shorten the life of the filament. General Electric bought the rights to use tantalum filaments and produced them in the US until 1913. From 1898 to around 1905, osmium was also used as a filament in lamps made by Carl Auer von Welsbach. The metal was so expensive that used lamps could be returned for partial credit. It could not be made for 110 V or 220 V so several lamps were wired in series for use on standard voltage circuits. These were primarily sold in Europe.
Sources: en.wikipedia.org
=== Active people === Several studies have concluded that active people and athletes may require elevated protein intake (compared to 0.8 g/kg) due to increase in muscle mass and sweat losses, as well as need for body repair and energy source. Indeed, it has been shown that protein contribute around 3% of the total energy expenditure during exercise. Suggested amounts vary from 1.2 to 1.4 g/kg for those doing endurance exercise to as much as 1.6-1.8 g/kg for strength exercise and up to 2.0 g/kg/day for older people, while a proposed maximum daily protein intake would be approximately 25% of energy requirements i.e. approximately 2 to 2.5 g/kg. However, many questions still remain to be resolved. In addition, some have suggested that athletes using restricted-calorie diets for weight loss should further increase their protein consumption, possibly to 1.8–2.0 g/kg, in order to avoid loss of lean muscle mass.
The Navier–Stokes equations (named after Claude-Louis Navier and George Gabriel Stokes) are differential equations that describe the force balance at a given point within a fluid. For an incompressible fluid with vector velocity field
The program was intended to be leading-edge, and many features of the program which were legal at the time, including Tribulus and intravenous vitamin C, were outlawed by 2014. Most of the supplements were administered away from Essendon's Windy Hill facilities. A total of 38 players consented to the program, although ASADA ultimately pursued cases against only 34 of those players, based on the supporting evidence it found through the investigation. The program of injections began in November 2011. In January 2012, Essendon's club doctor, Dr Bruce Reid, raised concerns about aspects of the program to the club. In particular, Dank had not liaised with Reid on the details of the program, which included administering substances that Reid had not personally approved, which was against the historical chain of accountability within the club. Reid wrote a letter to Hird and club general manager Paul Hamilton in January, recording his opinion that the substances Dank was administering were "playing at the edge" of legality with the potential to "read extremely badly in the press for [the] club", and that he was unconvinced that either the benefits or the side effects were well understood. At that point, the club's administrators agreed that Reid's approval was required in the future; however, evidence gathered during the investigation indicated Reid was largely kept out of the loop from that point on.
=== Radiological scope === Contrast agents with therapeutic properties have been under development for several years. One example is the design of contrast agents capable of releasing a chemotherapeutic agent locally at the target site, triggered by a stimulus provided by the operator. This localized approach aims to increase treatment efficacy and minimize side effects. For instance, ultrasound-based contrast media, such as microbubbles, can accumulate in hypervascularized tissues and release the active ingredient in response to ultrasound waves, thus targeting a specific area chosen by the sonographer. Another approach involves linking monoclonal antibodies (capable of targeting different molecular targets) to nanoparticles. This strategy enhances the drug's affinity and specificity towards the target and enables visualization of the treatment area, such as using superparamagnetic iron oxide particles detectable by magnetic resonance imaging. Additionally, these particles can be designed to release chemotherapy agents specifically at the site of binding, producing a local synergistic effect with antibody action. Integrating these methods with medical-nuclear techniques, which offer greater imaging sensitivity, may aid in target identification and treatment monitoring.
==== Sample preparation ==== In both conventional and in-situ dating, a thin section of the rock of interest is prepared. First, a thin layer of rock is cut by a diamond saw and ground to become optically flat. Then, it is mounted on a slide made of glass or resin, and ground smooth using abrasive grit. The final sample is usually only 30 μm thick.
Sources: en.wikipedia.org
Nemonapride, also previously known as emonapride and sold under the brand name Emilace, is an atypical antipsychotic which is used in the treatment of schizophrenia. It is taken by mouth. Side effects of nemonapride include akathisia, dystonia, hypokinesia, tremor, hypersalivation, and hyperprolactinemia, among others. The drug acts as a dopamine D2, D3, and D4 receptor antagonist. To a lesser extent, it is also a serotonin 5-HT1A receptor partial agonist. Structurally, nemonapride is a benzamide derivative and is related to sulpiride and other benzamides. Nemonapride was introduced for medical use in either 1991 or 1997. It was developed and marketed by Yamanouchi Pharmaceuticals. The drug is approved only in Japan and China.
=== Flowers and berries === When A. chilensis flowers at the end of spring, the white flowers are unisexual and small, eventually yielding a small edible fruit. The small purple-black berries that form are approximately 4 to 6 millimetres (0.16 to 0.24 in) in diameter and contain 4 to 8 angled seeds. A seven-year-old tree can produce up to 10 kilograms (22 lb) of berries per year. With fruit that tastes similar to blackberries, the species is known as the Chilean wineberry, and locally in Spanish as maqui or maque.
In September 2018, Panda Express announced its joint venture with Jollibee Foods Corporation to bring its stores in the Philippines. A year later, in December 2019, the first Panda Express restaurant in the Philippines opened at SM Megamall in Mandaluyong. More branches were opened, all located in the Greater Manila Area. The first Panda Express in Russia opened in Moscow in September 2018. However, in March 2022, Panda Express ceased all corporate support, including operations, marketing, and supply chain in response to the Russian war against Ukraine. Panda Express previously had eight sites in Japan that were operated under a franchise agreement that later lapsed. In November 2016, the company returned to the country by opening a new restaurant in Kawasaki. This restaurant is operated as part of a joint partnership with Ippudo. As of August 2022, there were nine restaurants in the country. In October 2020, the South China Morning Post reported that a fake Panda Express restaurant in the southwestern Chinese city of Kunming had been reported for trademark infringement, and was closed during an investigation. The reportedly fake restaurant used the same Panda Express logo, and its menu reportedly included the same Kung Pao Chicken and Tangerine Peel Chicken as the company's restaurants. In August 2022, Panda Express opened its first European site in Kaiserslautern Military Community Center food court, Ramstein Air Base, Germany. The first German public location will open at the train station Zoologischer Garten in Berlin.
=== Antigen recognition === Garcia's earliest research as a graduate student at Johns Hopkins University focused on understanding how anti-idiotyopic antibodies recognize peptide antigens. As a postdoctoral scholar at The Scripps Research Institute, Garcia conducted a groundbreaking study that revealed how T cells of the immune system survey peptides presented by major histocompatibility complex proteins (MHC), thus allowing them to distinguish between "self" and "non-self". Garcia's research led to the first visualization of a T cell receptor (TCR) bound to a peptide-MHC (pMHC) complex and was published in the journal Science in 1996. Garcia's 1996 article on the TCR-MHC interaction has had broad impact in the fields of immunology and immunotherapy. At Stanford University, the Garcia Laboratory reported the structure of the pre-B cell receptor (pre-BCR) in 2007, which revealed how pre-BCRs oligomerize to signal in the absence of antigen. Garcia's group has also authored several additional landmark articles exploring various aspects of TCR-pMHC interactions, including the first structure of a γδ TCR-pMHC complex, the molecular basis for dual recognition of "self" and "foreign" MHCs by TCRs, insights into the germline basis of TCR/MHC interactions, the extent of cross-reactivity in the TCR repertoire, and elucidation of the structural trigger for TCR signaling. In Garcia's most recent work, his lab developed a peptide-MHC library technology that has enabled the discovery of antigens for orphan T cell receptors, such as those resident in tumors.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.